Karyopharm Therapeutics Inc.'s submission of Phase III data near the end of the review cycle for the company's multiple myeloma treatment Xpovio (selinexor) helped to save the drug from a complete response letter and ultimately score an accelerated approval following a three-month user fee date extension, a US Food and Drug Administration review document shows.
The FDA granted Xpovio, a nuclear export inhibitor, accelerated approval on 3 July 2019 in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?